Pathology in United States: Ariad Pharmaceuticals: PharmaVitae Report

• Publication date: June 2012
• Report size: 34 pages

This analysis evaluates the firm ’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the firm ’s historical and projection financial performance. The market research report also gives an in-depth analysis of the firm ’s key prescription pharmaceutical product, and provides a projection sales performance for this drug....

This analysis evaluates the firm ’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the firm ’s historical and projection financial performance. The market research report also gives an in-depth analysis of the firm ’s key prescription pharmaceutical product, and provides a projection sales performance for this drug.Gain insight into Ariad Pharmaceuticals' strategic vision Analyze firm revenue projections by productAriad’s most advanced product candidate is ponatinib, which the industry player believes has potential in hematological cancers and solid tumors. It is in a pivotal Phase II trial and Ariad plans to file for industry ing approval of ponatinib in the US and Europe in the third quarter of 2012.Ariad’s second-closest product to approval is AP26112, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). These are both targets in non-small cell lung cancer (NSCLC). Depending on the outcome of a Phase I/II trial, Ariad envisions starting a pivotal trial in NSCLC patients in 2013.Compare Ariad Pharmaceuticals' performance against key competitors in the prescription pharmaceutical segment Assess how successful Ariad Pharmaceuticals will be in obtaining industry ing approval for its first product

Pathology Industry in Europe

ABOUT THIS REPORT•PharmaVitae Explorer database
•Chapter structure - Sales and product analysis
- Financial analysis

•Data sourcing - Analyst consensus

EXECUTIVE SUMMARY•Company introduction - Recent developments
- Corporate relationships

•Strategic overview
•SWOT analysis - Strengths
- Weaknesses
- Opportunities
- Threats

SALES AND PRODUCT ANALYSIS•Sales overview
•Portfolio overview - Product sales

•Ponatinib - Chronic myeloid leukemia
- Acute lymphoblastic leukemia
- Current treatments: industry ed drugs for CML do not have activity against the T315I mutation
- Current treatments: first-line treatment of ALL consists of combination chemotherapy regimens
- Clinical trials
- Factors affecting ponatinib approval and use
- Key projecting hypothesis s

•Other products - Ridaforolimus

FINANCIAL ANALYSIS•Financial performance overview - Operating costs and profit analysis, 2005–11
- Operating costs and profit analysis, 2011–17

APPENDIX•References - Datamonitor reports

•Exchange rates

TABLES•Table: Ariad Pharmaceuticals product portfolio overview ($m), 2012–17
•Table: Ariad Pharmaceuticals’ clinical trial program includes one pivotal Phase II trial and a planned Phase III trial
•Table: Phase II PACE trial data with ponatinib
•Table: Ponatinib US sales projection model
•Table: Ponatinib EU sales projection model
•Table: Ariad operating revenue/cost analysis ($m), 2005–11
•Table: Ariad operating revenue/cost analysis ($m), 2011–17
•Table: Exchange rates, 2011

FIGURES•Figure: PharmaVitae Explorer
•Figure: Ariad prescription pharmaceutical performance, sales ($m) and growth rate (%), 2012–17
•Figure: Ariad Pharmaceuticals key product sales ($m), 2012–17
•Figure: Ariad Pharmaceuticals operating/cost performance ($m), 2005–17

Companies mentioned

Amlin plc, Hutchison 3G UK Limited